ArriVent BioPharma, Inc. Stock 12‑Month Price Target Raised to $24, Implies 14% Upside

Analysts raised ArriVent BioPharma's 12-month price target from $22.91 to $24, suggesting 14% upside. The consensus rating remains 'Buy' among 12 analysts. Forecasts range from $15 to $30 per share, according to estimates.

Original reporting
Published Oct 26, 2026, 10:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 10:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ArriVent BioPharma, Inc. Stock 12‑Month Price Target Raised to $24, Implies 14% Upside — source image
Decision brief

The 30-second read

Med
01

Why it matters

The upward revision reflects analyst optimism but lacks fresh company‑specific catalysts.

02

Market read

Analyst target increase may prompt short‑term buying interest.

03

What to watch

No new clinical data disclosed; the raise is purely analyst opinion.

Relevance 6/10Novelty 7/10Timing: immediate

Background

ArriVent BioPharma is a clinical‑stage biotech focused on rare diseases.

Market effects

May lift sentiment in the biotech/clinical‑stage sector.

Limited to U.S. biotech investors.

Minor, confined to ARVT shareholders.

Counterpoint

Target raises can be premature if upcoming trial data disappoints.

Key entities

  • ArriVent BioPharma, Inc.

    Subject of the price‑target upgrade.

Related articles

$AVBPHighAI 8/10

ArriVent Reports Q3 2026 Results; FURVENT Misses Primary Endpoint, ALPACCA Enrollment Continues

ArriVent BioPharma (AVBP) reported Q3 2026 results, with R&D expenses at $38.9M and net loss widening to $40.3M. The FURVENT trial missed its primary endpoint, but ALPACCA enrollment continues. ARR-217 showed promising preliminary data, and ARR-002's first-in-human study began. Cash reserves are $393.2M, expected to last until mid-2028. AVBP stock closed at $14.16, up 3.81%.

$AVBPMed

ArriVent BioPharma Reports Third Quarter 2026 Financial Results

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ArriVent BioPharma Reports Third Quarter 2026 Financial Results · Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC · Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO · Dosed

$AVBPMedAI 8/10

Truist raises ArriVent BioPharma stock price target on drug data

Truist raised its price target for ArriVent BioPharma (AVBP) to $21, citing positive early data for ARR-217 in treating metastatic colorectal cancer. The drug showed a 44.8% preliminary response rate and favorable tolerability. Truist expects Phase 1b data in early 2027. AVBP's stock is down 27% from last week, trading at $15.26. Other analysts have mixed views following a Phase 3 trial failure for firmonertinib.

$AVBPMedAI 9/10

ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

ArriVent BioPharma (NASDAQ:AVBP) reported ARR-217 showed a 44.8% response rate in colorectal cancer study. Key data: 50% in RAS-mutant, 42% in RAS wild-type, 43.5% in irinotecan-treated patients. Phase Ib study ongoing; Phase III trial planned by 2027 end. Common adverse events included anemia, neutropenia, and diarrhea. Company also advancing ARR-002 and firmonertinib in NSCLC.